Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Lowering of large bowel butyrate levels in healthy populations is unlikely to be beneficial.

Conlon MA, Bird AR, Clarke JM, Le Leu RK, Christophersen CT, Lockett TJ, Topping DL.

J Nutr. 2015 May;145(5):1030-1. doi: 10.3945/jn.114.209460. No abstract available.

2.

A prediction model for colon cancer surveillance data.

Good NM, Suresh K, Young GP, Lockett TJ, Macrae FA, Taylor JM.

Stat Med. 2015 Aug 15;34(18):2662-75. doi: 10.1002/sim.6500. Epub 2015 Apr 6.

PMID:
25851283
3.

Bioequivalence of n-3 fatty acids from microencapsulated fish oil formulations in human subjects.

Sanguansri L, Augustin MA, Lockett TJ, Abeywardena MY, Royle PJ, Mano MT, Patten GS.

Br J Nutr. 2015 Mar 14;113(5):822-31. doi: 10.1017/S000711451400436X. Epub 2015 Feb 25.

PMID:
25711158
4.

Resistant starch alters colonic contractility and expression of related genes in rats fed a Western diet.

Patten GS, Kerr CA, Dunne RA, Shaw JM, Bird AR, Regina A, Morell MK, Lockett TJ, Molloy PL, Abeywardena MY, Topping DL, Conlon MA.

Dig Dis Sci. 2015 Jun;60(6):1624-32. doi: 10.1007/s10620-015-3537-8. Epub 2015 Jan 24.

PMID:
25616610
5.

Ideal colonoscopic surveillance intervals to reduce incidence of advanced adenoma and colorectal cancer.

Good NM, Macrae FA, Young GP, O'Dywer J, Slattery M, Venables W, Lockett TJ, O'Dwyer M.

J Gastroenterol Hepatol. 2015 Jul;30(7):1147-54. doi: 10.1111/jgh.12904.

PMID:
25611802
6.

Butyrylated starch affects colorectal cancer markers beneficially and dose-dependently in genotoxin-treated rats.

Toden S, Lockett TJ, Topping DL, Scherer BL, Watson EJ, Southwood JG, Clarke JM.

Cancer Biol Ther. 2014;15(11):1515-23. doi: 10.4161/15384047.2014.955764.

7.

Little evidence for association between the TGFBR1*6A variant and colorectal cancer: a family-based association study on non-syndromic family members from Australia and Spain.

Ross JP, Lockett LJ, Tabor B, Saunders IW, Young GP, Macrae F, Blanco I, Capella G, Brown GS, Lockett TJ, Hannan GN.

BMC Cancer. 2014 Jul 1;14:475. doi: 10.1186/1471-2407-14-475.

8.

A panel of genes methylated with high frequency in colorectal cancer.

Mitchell SM, Ross JP, Drew HR, Ho T, Brown GS, Saunders NF, Duesing KR, Buckley MJ, Dunne R, Beetson I, Rand KN, McEvoy A, Thomas ML, Baker RT, Wattchow DA, Young GP, Lockett TJ, Pedersen SK, Lapointe LC, Molloy PL.

BMC Cancer. 2014 Jan 31;14:54. doi: 10.1186/1471-2407-14-54.

9.

Repair and removal of azoxymethane-induced O6-methylguanine in rat colon by O6-methylguanine DNA methyltransferase and apoptosis.

Nyskohus LS, Watson AJ, Margison GP, Le Leu RK, Kim SW, Lockett TJ, Head RJ, Young GP, Hu Y.

Mutat Res. 2013 Dec 12;758(1-2):80-6. doi: 10.1016/j.mrgentox.2013.10.001. Epub 2013 Oct 16.

PMID:
24140386
10.

Crohn’s disease: towards improving postsurgical outcomes.

Lockett TJ, Kamm MA, De Cruz P, Kirkwood CD.

Med J Aust. 2013 Oct 21;199(8):524. No abstract available.

PMID:
24138368
11.

Identification of potential pathways involved in induction of apoptosis by butyrate and 4-benzoylbutyrate in HT29 colorectal cancer cells.

Fung KY, Ooi CC, Lewanowitsch T, Tan S, Tan HT, Lim TK, Lin Q, Williams DB, Lockett TJ, Cosgrove LJ, Chung MC, Head RJ.

J Proteome Res. 2012 Dec 7;11(12):6019-29. doi: 10.1021/pr3007107. Epub 2012 Nov 5.

PMID:
23057685
12.

Resistant starches protect against colonic DNA damage and alter microbiota and gene expression in rats fed a Western diet.

Conlon MA, Kerr CA, McSweeney CS, Dunne RA, Shaw JM, Kang S, Bird AR, Morell MK, Lockett TJ, Molloy PL, Regina A, Toden S, Clarke JM, Topping DL.

J Nutr. 2012 May;142(5):832-40. doi: 10.3945/jn.111.147660. Epub 2012 Mar 28.

13.

Butyrate delivered by butyrylated starch increases distal colonic epithelial apoptosis in carcinogen-treated rats.

Clarke JM, Young GP, Topping DL, Bird AR, Cobiac L, Scherer BL, Winkler JG, Lockett TJ.

Carcinogenesis. 2012 Jan;33(1):197-202. doi: 10.1093/carcin/bgr254. Epub 2011 Nov 10.

14.

Is the tissue persistence of O(6)-methyl-2'-deoxyguanosine an indicator of tumour formation in the gastrointestinal tract?

Tan SL, Gerber JP, Cosgrove LJ, Lockett TJ, Clarke JM, Williams DB, Head RJ.

Mutat Res. 2011 Apr 3;721(2):119-26. doi: 10.1016/j.mrgentox.2010.12.016. Epub 2011 Feb 2.

PMID:
21295156
15.

Structure-activity relationship of butyrate analogues on apoptosis, proliferation and histone deacetylase activity in HCT-116 human colorectal cancer cells.

Ooi CC, Good NM, Williams DB, Lewanowitsch T, Cosgrove LJ, Lockett TJ, Head RJ.

Clin Exp Pharmacol Physiol. 2010 Sep;37(9):905-11. doi: 10.1111/j.1440-1681.2010.05403.x. Epub 2010 May 24.

PMID:
20497425
16.

Efficacy of butyrate analogues in HT-29 cancer cells.

Ooi CC, Good NM, Williams DB, Lewanowitsch T, Cosgrove LJ, Lockett TJ, Head RJ.

Clin Exp Pharmacol Physiol. 2010 Apr;37(4):482-9. doi: 10.1111/j.1440-1681.2009.05335.x. Epub 2009 Nov 23.

PMID:
19930426
17.

Redesigned and chemically-modified hammerhead ribozymes with improved activity and serum stability.

Hendry P, McCall MJ, Stewart TS, Lockett TJ.

BMC Chem Biol. 2004 Dec 9;4(1):1.

18.

Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus.

Wang XY, Martiniello-Wilks R, Shaw JM, Ho T, Coulston N, Cooke-Yarborough C, Molloy PL, Cameron F, Moghaddam M, Lockett TJ, Webster LK, Smith IK, Both GW, Russell PJ.

Gene Ther. 2004 Nov;11(21):1559-67.

PMID:
15343359
19.

Identifying ribozyme-accessible sites using NUH triplet-targeting gapmers.

Mir AA, Lockett TJ, Hendry P.

Nucleic Acids Res. 2001 May 1;29(9):1906-14.

20.

Small, efficient hammerhead ribozymes.

McCall MJ, Hendry P, Mir AA, Conaty J, Brown G, Lockett TJ.

Mol Biotechnol. 2000 Jan;14(1):5-17.

PMID:
10911611
Items per page

Supplemental Content

Loading ...
Write to the Help Desk